Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 1;213(5):567-576.
doi: 10.4049/jimmunol.2300781.

Endometriotic Tissue-derived Exosomes Downregulate NKG2D-mediated Cytotoxicity and Promote Apoptosis: Mechanisms for Survival of Ectopic Endometrial Tissue in Endometriosis

Affiliations

Endometriotic Tissue-derived Exosomes Downregulate NKG2D-mediated Cytotoxicity and Promote Apoptosis: Mechanisms for Survival of Ectopic Endometrial Tissue in Endometriosis

Emma Björk et al. J Immunol. .

Abstract

Endometriosis, affecting 10% of women, is defined as implantation, survival, and growth of endometrium-like/endometriotic tissue outside the uterine cavity, causing inflammation, infertility, pain, and susceptibility to ovarian cancer. Despite extensive studies, its etiology and pathogenesis are poorly understood and largely unknown. The prevailing view is that the immune system of endometriosis patients fails to clear ectopically disseminated endometrium from retrograde menstruation. Exosomes are small extracellular vesicles that exhibit immunomodulatory properties. We studied the role of endometriotic tissue-secreted exosomes in the pathophysiology of endometriosis. Two exosome-mediated mechanisms known to impair the immune response were investigated: 1) downregulation of NKG2D-mediated cytotoxicity and 2) FasL- and TRAIL-induced apoptosis of activated immune cells. We showed that secreted endometriotic exosomes isolated from supernatants of short-term explant cultures carry the NKG2D ligands MICA/B and ULBP1-3 and the proapoptotic molecules FasL and TRAIL on their surface, i.e., signature molecules of exosome-mediated immune suppression. Acting as decoys, these exosomes downregulate the NKG2D receptor, impair NKG2D-mediated cytotoxicity, and induce apoptosis of activated PBMCs and Jurkat cells through the FasL- and TRAIL pathway. The secreted endometriotic exosomes create an immunosuppressive gradient at the ectopic site, forming a "protective shield" around the endometriotic lesions. This gradient guards the endometriotic lesions against clearance by a cytotoxic attack and creates immunologic privilege by induction of apoptosis in activated immune cells. Taken together, our results provide a plausible, exosome-based mechanistic explanation for the immune dysfunction and the compromised immune surveillance in endometriosis and contribute novel insights into the pathogenesis of this enigmatic disease.

PubMed Disclaimer

Conflict of interest statement

The authors have no financial conflicts of interest.

Figures

None
Graphical abstract
FIGURE 1.
FIGURE 1.
Nanoparticle tracking analysis (NTA) and electron micrographs of exosomes (exo) isolated from short-term endometriotic tisesue cultures and serum from endometriosis patients and healthy controls. (A and B) Size distribution of representative endometriotic tissue exosomes and serum samples (A) and mean endometriotic tissue exosome size (n = 5) (B) compared with the size of endometriosis serum exosomes (n = 7). (C) Representative micrographs of negatively stained endometriotic tissue exosomes showing size, purity, and the typical cup shape, and immunoelectron microscopy with mAbs and silver-enhanced immunogold staining of the tetraspanins CD63 and CD81; and CA125, often used as an ovarian cancer marker. (D) Representative experiment of NTA analysis and negative contrast staining of exosomes from serum of healthy controls.
FIGURE 2.
FIGURE 2.
Endometriotic tissue–derived exosomes (exo) carry NKG2D ligands that downregulate the NKG2D receptor on PBMCs from healthy donors. (A) Immunoelectron micrographs of endometriotic tissue exosomes expressing the NKG2D ligands MICA/B and ULBP1-3. (B) Immunoflow cytometry of endometriotic tissue exosomes captured on mAb-coated latex beads showing surface expression of members of the MICA/B and ULBP families. The black curve represents negative controls with isotype-matched mAbs. (C) MICA/B and ULBP1-3 expression, measured by MFI normalized to isotype-matched mAb control (= 1), on endometriotic tissue- and endometriosis serum exosomes; note the higher ULBP ligand expression on endometriotic tissue exosomes (n = 4). (D) A representative experiment showing downregulation of the NKG2D receptor expression on PBMCs from healthy donors, assessed by MFI before and after 24-h incubation with native endometriotic-tissue exosomes or with the same exosomes blocked by anti-CD63 Abs. Isotype-matched control mAbs (DAKO) were used in the negative control. (E) Average results of seven experiments like the one shown in (D), measuring NKG2D receptor downregulation in the absence and presence of native or blocked exosomes from endometriotic tissue, p < 0.001. (F and G) Average results of six experiments with endometriosis serum exosomes (F) and four experiments with healthy donors’ serum exosomes (G) like the ones shown in (D) and (E).
FIGURE 3.
FIGURE 3.
Endometriotic tissue–derived NKG2D ligand-carrying exosomes (exo) impair the killing ability of PBMCs from healthy donors. (A) NKG2D-mediated cytotoxicity was assessed with PBMCs as effector cells and the erythroleukemia cell line K562 as target cells (E:T ratio 40:1) in the presence/absence of native or mAb-blocked endometriotic tissue exosomes (n = 4). Note that the presence of native exosomes reduced the cytotoxicity to a degree comparable to blocking the target or effector cells (p = 0.0001). Treatment of the exosomes with a mAb mixture of NKG2D ligands or anti-CD63 mAb reversed the suppression to nonsignificant levels, compared with untreated target and effector cells. Used supernatant, left after isolation of exosomes, did not affect cytotoxicity. (B) Experiments similar to those in (A) with exosomes isolated from serum from endometriosis patients (n = 3). (C) Experiments similar to those in (A) with exosomes from healthy donors (n = 6).
FIGURE 4.
FIGURE 4.
Endometriotic tissue–derived exosomes (exo) carry functional FasL and TRAIL that trigger apoptosis of Jurkat cells in vitro. (A) Immunoelectron microscopy of endometriotic tissue exosomes stained with mAbs against the proapoptotic ligands FasL and TRAIL. (B) Immunoflow cytometry of endometriotic tissue exosomes captured on latex beads coated with mAbs against FasL and TRAIL. The black curves represent negative isotype-matched mAb controls. (C) Average expression of FasL and TRAIL, measured by MFI normalized to isotype-matched mAb control (= 1) on endometriotic tissue exosomes compared with endometriosis serum exosomes and exosomes from healthy donors (n = 4). (D and E) Apoptosis of Jurkat cells induced by endometriotic tissue–derived exosomes (D) and by endometriosis serum exosomes (E) (n = 4). (F and G) Apoptosis of activated PBMCs induced by endometriotic tissue–derived exosomes (F) and by endometriosis serum exosomes (G) (n = 3).
FIGURE 5.
FIGURE 5.
Schematic presentation of two immunosuppressive mechanisms driven by endometriotic tissue–derived exosomes. The endometriotic tissue, here presented by diagnostic micrographs stained for CD 10, estrogen receptor (ER), and vimentin (VIM), secretes exosomes carrying the NKG2D receptor ligands MICA/B and ULBP 1–3 and the proapoptotic ligands FasL and TRAIL. MICA/B and ULBP 1–3 carrying exosomes internalize the NKG2D receptor on NK cells and impair their cytotoxic ability. Exosomes carrying FasL and TRAIL induce apoptosis of activated immune cells. These mechanisms protect the endometriotic tissue from immune attack and allow its persistence at ectopic sites.

Similar articles

Cited by

References

    1. Zondervan, K. T., Becker C. M., Missmer S. A.. 2020. Endometriosis. N. Engl. J. Med. 382: 1244–1256. - PubMed
    1. Harada, T., Iwabe T., Terakawa N.. 2001. Role of cytokines in endometriosis. Fertil. Steril. 76: 1–10. - PubMed
    1. Cramer, D. W., Missmer S. A.. 2002. The epidemiology of endometriosis. Ann. N. Y. Acad. Sci. 955: 11–22. - PubMed
    1. Sampson, J. A. 1927. Metastatic or embolic endometriosis, due to the menstrual dissemination of endometrial tissue into the venous circulation. Am. J. Pathol. 3: 93–110.43. - PMC - PubMed
    1. Giudice, L. C., Kao L. C.. 2004. Endometriosis. Lancet 364: 1789–1799. - PubMed

MeSH terms

Substances